BC Week In Review | Aug 3, 2015
Company News

Ablynx, Taisho deal

Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat rheumatoid arthritis. Ablynx will receive $3 million up front and is eligible to receive undisclosed development and commercial milestones and royalties. Taisho...
BC Week In Review | Sep 8, 2014
Company News

Ablynx, Eddingpharm deal

Ablynx granted Eddingpharm exclusive rights in China, including Hong Kong and Macao, and Taiwan to develop and commercialize ozoralizumab ( ATN-103 ) for all indications. Ablynx will receive €2 million ($2.6 million) up front, payable in two...
BC Week In Review | Jul 9, 2012
Clinical News

Ozoralizumab: Extension study data

Data from a 48-week, open-label extension study in 231 evaluable patients who completed 1 of 2 double-blind, 16-week Phase II trials showed that ozoralizumab given every 4 weeks led an ACR20 response rate of 84.4%...
BioCentury | Nov 14, 2011

Ablynx juggling

Ablynx juggling A third Nanobody deal with Merck Serono S.A. wasn't a charm for Ablynx N.V. (Euronext:ABLX), whose shares have been weighed down by disappointments involving two Phase II programs in as many weeks. Last...
BC Week In Review | Nov 7, 2011
Company News

Ablynx, Pfizer deal

Pfizer terminated a 2006 deal and returned worldwide rights to develop and commercialize Nanobodies against tumor necrosis factor (TNF) alpha to Ablynx, including ATN-103 and PF-05230905. Ablynx said it will gain certain IP relating to...
BioCentury | Nov 7, 2011

Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) fell SEK7.60 (27%) to SEK20.30 on Wednesday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it would be "premature" to submit an NDA for laquinimod at this time. Teva, which had...
BC Extra | Nov 5, 2011
Company News

Ablynx off on Pfizer deal termination

Ablynx N.V. (Euronext:ABLX) fell EUR 0.65 (18%) to EUR 2.93 on Friday after Pfizer Inc. (NYSE:PFE) terminated a 2006 deal and returned rights to Nanobodies against tumor necrosis factor (TNF) alpha , including ATN-103 and PF-05230905....
BC Week In Review | May 23, 2011
Clinical News

Ozoralizumab: Phase II data

Top-line data from a double-blind, dose-escalation, international Phase II trial in 252 patients with active RA on stable methotrexate therapy showed that 80 mg ozoralizumab every 4 weeks met the pre-defined primary efficacy endpoint of...
BioCentury | May 23, 2011

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.67 (14%) to $30.38 on Friday, while partner Biogen Idec Inc. (NASDAQ:BIIB) was up $0.39 to $97.11, after EMA's CHMP reversed a prior decision and recommended conditional approval...
BC Extra | May 18, 2011
Clinical News

Ablynx's ozoralizumab meets RA endpoint

Ablynx N.V. (Euronext:ABLX) said ozoralizumab met the primary endpoint in a Phase II trial to treat rheumatoid arthritis. The anti- tumor necrosis factor (TNF) alpha nanobody significantly improved ACR20 response rate at week 16 vs....
Items per page:
1 - 10 of 10